NIDDK Central Repository - Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.

An official website of the United States government

This repository is under review for potential modification in compliance with Administration directives.

NIDDK Central Repository

Publication Information

DOI

10.1016/j.xkme.2023.100639

PubMed ID

37250503

Public Release Type

Journal

Publication Year

2023

Affiliation

Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL.; RTI Health Solutions, Research Triangle Park, NC.; RTI Health Solutions, Research Triangle Park, NC.; RTI Health Solutions, Research Triangle Park, NC.; Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, MD.; Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, MD.; Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, MD.

Authors

Chebib Fouad T, Zhou Xiaolei, Garbinsky Diana, Davenport Eric, Nunna Sasikiran, Oberdhan Dorothee, Fernandes Ancilla

Studies

HALT PKD

Abstract

Tolvaptan is indicated for treatment of patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. Participants aged 56-65 years constituted a small proportion of the Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trial population. We assessed effects of tolvaptan on estimated glomerular filtration rate (eGFR) decline in participants aged >55 years.